Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.53 |
| ▸ | TARS1 | P26639 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 8/20 | 0.50 |
| ▸ | MMP13 | P45452 | 8/20 | 0.50 |
| ▸ | MMP1 | P03956 | 5/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.48 |
| ▸ | MMP14 | P50281 | 2/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103556 | 0.86 | ALDH1A1 (0.50) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL3088414 | 0.81 | ALDH1A1 (0.49) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL3093141 | 0.81 | LARS1 (0.53) | MCL1BCL2L1 | |
| Hydrochloric Acid SCHEMBL3085657 | 0.80 | LARS1 (0.52) | MCL1BCL2L1 | |
| SCHEMBL17943672 | 0.80 | BCL2L1 (0.58) | MCL1BCL2L1TARS1MMP2MMP13 | |
| SCHEMBL21967031 | 0.79 | MMP2 (0.51) | MCL1BCL2L1TARS1MMP2MMP13 | |
| SCHEMBL3085861 | 0.78 | MMP1 (0.47) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL7749432 | 0.77 | MMP2 (0.59) | MCL1BCL2L1TARS1MMP2MMP13 | |
| SCHEMBL3097522 | 0.76 | RAPGEF3 (0.57) | — | |
| SCHEMBL3083514 | 0.76 | ALDH1A1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | MCL1 4465/4885BCL2L1 3351/4885TARS1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.